Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
SynopsisI

Does intensified cholesterol lowering provide greater protection from cardiovascular events among patients with stable coronary artery disease?

Daniel G. Hackam
CMAJ May 10, 2005 172 (10) 1294-1295; DOI: https://doi.org/10.1503/cmaj.050418
Daniel G. Hackam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading
  • © 2005 CMA Media Inc. or its licensors

LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352(14):1425-35.

Background: It is unknown whether intensive lowering of low-density lipoprotein (LDL) cholesterol levels to less than 2.6 mmol/L decreases the risk of cardiovascular events among patients with stable coronary artery disease (CAD).

Design: This double-blind study randomly assigned 10 001 patients with a history of myocardial infarction, angina or coronary revascularization to treatment with 10 mg atorvastatin per day or 80 mg per day after an 8-week, open-label run-in period. The primary outcome was a composite of death from CAD, nonfatal myocardial infarction, resuscitated cardiac arrest or stroke. All analyses were performed by intention-to-treat according to the first event experienced.

Results: The average patient enrolled was 61 years old, male (81%), white (94%), had a history of coronary revascularization (82%) and was at some distance from the qualifying event (mean 1.7 years). Concomitant medications included aspirin in 88% of cases, β-blockers in 55%, angiotensin-converting-enzyme inhibitors in 28% and nitrates in 32%.1 Comorbidities such as heart failure, cerebrovascular disease and diabetes mellitus were infrequent (all < 15%).

The median follow-up was 4.9 years. Serum LDL levels were reduced from a baseline of 3.9 mmol/L to 2.6 and 2.0 mmol/L among those assigned to atorvastatin 10 mg per day and 80 mg per day respectively. The primary outcome was reduced by 22% (95% confidence interval [CI] 11–31) in the high-dose group, which corresponded to an absolute risk reduction of 2.2%. Myocardial infarction, stroke and CAD-related death were each reduced by 20%–25%, but total mortality was unaffected (hazard ratio [HR] 1.01, 95% CI 0.85–1.19). Treatment-related adverse events and persistently raised liver enzyme levels were more frequent in the high-dose group (8.1% v. 5.8% and 1.2% v. 0.2% respectively, p < 0.001 for both) with no increase in muscle symptoms or rhabdomyolysis reported.

Commentary: Recent evidence involving patients with acute coronary syndromes suggests intensive cholesterol lowering with high-dose statin therapy confers added benefit over a less aggressive, lower dose approach.2 However, until now, it was unknown whether such benefits could be extended to the broader population of patients with stable CAD. Considered in the light of previous placebo-controlled trials, the results of this study suggest that high-dose atorvastatin reduces the risk of cardiovascular events in this population by 40%–50%. However, there are two caveats.

First, the study protocol specified no fewer than 18 exclusion criteria. In particular, patients over 75 years and those with uncontrolled hypertension or diabetes; significant valvular, gastrointestinal, hepatic or renal disease; or an ejection fraction less than 30% were excluded.1 Although it is conceivable that these patients may derive a greater absolute benefit because of higher baseline risk, the favourable risk–benefit ratio of this trial cannot be generalized to patients with multiple severe comorbidities, very old patients or those taking other lipid-modifying drugs.

Second, it is noteworthy that the trend toward reduction of cardiovascular death was matched by a nearly significant increase in death from noncardiovascular causes (HR 1.25, 95% CI 0.99– 1.57; p = 0.07), a finding the investigators attributed to chance.

Other cholesterol-lowering strategies have been shown to be helpful in high-risk patients. For example, use of simvastatin 40 mg per day (compared with placebo) was found to be broadly beneficial among patients with peripheral artery disease, cerebrovascular disease or diabetes.3 Also, an approach targeting high-density (HDL) cholesterol with fibrates or niacin also seems to confer independent benefit in patients with vascular disease.4

Practice implications: It is increasingly clear that patients across the spectrum of CAD benefit substantially from aggressive cholesterol lowering to an LDL level as low as 2.0 mmol/L. It remains unclear whether maximal lowering of LDL levels and raising HDL levels should be combined or which patients might best respond to which approach; further trials are now studying these options. Since there is evidence that adverse events due to atorvastatin are somewhat increased at higher doses, patients with stable CAD might still best be started on a low dose of a statin, with the dosage increased to the maximum recommended among those who tolerate such therapy.

References

  1. 1.↵
    Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C; TNT Steering Committee Members and Investigators. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 2004;93(2):154-8.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350(15):1495-504.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7-22.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Whitney EJ, Krasuski RA, Personius BE, Michalek JE, Maranian AM, Kolasa MW, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005;142(2):95-104.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 172 (10)
CMAJ
Vol. 172, Issue 10
10 May 2005
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Does intensified cholesterol lowering provide greater protection from cardiovascular events among patients with stable coronary artery disease?
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Does intensified cholesterol lowering provide greater protection from cardiovascular events among patients with stable coronary artery disease?
Daniel G. Hackam
CMAJ May 2005, 172 (10) 1294-1295; DOI: 10.1503/cmaj.050418

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Does intensified cholesterol lowering provide greater protection from cardiovascular events among patients with stable coronary artery disease?
Daniel G. Hackam
CMAJ May 2005, 172 (10) 1294-1295; DOI: 10.1503/cmaj.050418
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Applying the 2005 Canadian Hypertension Education Program recommendations: 4. Managing uncomplicated hypertension
  • A newborn requiring selective bronchial intubation
  • Does β-blocker prophylaxis improve survival after major noncardiac surgery?
Show more Synopsis

Similar Articles

Collections

  • Topics
    • Drugs: cardiovascular system

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire